“Adaptive radiotherapy has traditionally been complex, costly, and limited to well-resourced centers,” said Trang Nguyen, CEO and founder of SeeTreat. “We designed ART.1 to perform background analysis of every fraction, prioritizing major deviation, and give the clinical team a second set of eyes—without adding to the workload, resources or time.”
What Makes ART.1 Different: Saving Days,…